19 August 2024 - Application based on the TRANSCEND FL trial in which Breyanzi showed deep and durable responses and a consistent and well-established safety profile.

Bristol Myers Squibb today announced that the EMA has validated its type II variation application to expand the indication for Breyanzi (lisocabtagene maraleucel), a CD19 directed chimeric antigen receptor T cell therapy, to include the treatment of adult patients with relapsed or refractory follicular lymphoma who have received two or more prior lines of systemic therapy.

Read BMS press release